BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Zafgen 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: 617-236-0535 Fax: 617-249-0490


SEARCH JOBS



Segment
Start Up





 Company News
Zafgen Announces Initial Results From Phase 2a Study Of Beloranib In Patients With Prader-Willi Syndrome 1/15/2014 8:05:35 AM    More...
Zafgen To Present At 32nd Annual J.P. Morgan Healthcare Conference 1/9/2014 6:50:43 AM    More...
Zafgen Appoints Chief Commercial Officer And New Member Of Board Of Directors 1/9/2014 6:39:24 AM    More...
Zafgen Racks Up $45 Million Series E Round 12/4/2013 6:30:40 AM    More...
Zafgen's Obesity Drug Clears A Hurdle, Helps Patients Lose Up To 24 Pounds In Phase 2 Study 11/15/2013 7:19:08 AM    More...
Zafgen's Obesity Drug Targets Body, Not the Mind; With an Ex-Novartis AG (NVS) Exec in Charge, Co. May Have an Edge Over Its Competitors 8/27/2013 7:44:18 AM    More...
Zafgen's Obesity Drug Continues to Cut the Fat in Phase 2 Trial 6/24/2013 8:16:31 AM    More...
Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer 1/4/2013 7:19:45 AM    More...
Zafgen Secures $21 Million in Series D Financing 12/4/2012 6:55:28 AM    More...
Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity 11/6/2012 11:07:59 AM    More...
1234

//-->